Segment Reporting - Schedule of Adjusted Net Income (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2026	Sep. 30, 2025	Sep. 30, 2026	Sep. 30, 2025
Segment Reporting [Line Items]
Net loss	$ (12,327)	$ (7,635)	$ (93,383)	$ (3,355)
Depreciation and amortization expense	3,300	2,400	9,100	6,800
Stock-based compensation expense	8,253	10,586	23,591	22,382
Change in fair value of financial liabilities	0	(3,401)	2,760	(2,320)
Interest expense, net	1,779	562	3,681	2,019
Impairment loss	0	0	31,287	0
Loss on extinguishment of debt	0	0	6,565	0
Other	94	174	138	(274)
GeneDx Segment
Segment Reporting [Line Items]
Net loss	(12,327)	(7,635)	(93,383)	(3,355)
Depreciation and amortization expense	1,687	1,374	4,875	3,838
Stock-based compensation expense	371	219	1,312	580
Restructuring costs	18	0	65	0
Impairment loss	0	0	31,287	0
GeneDx Segment | Segment Reconciling Items
Segment Reporting [Line Items]
Depreciation and amortization expense	6,895	6,474	20,418	18,343
Stock-based compensation expense	8,253	10,586	23,591	22,382
Restructuring costs	867	128	4,601	759
Change in fair value of financial liabilities	0	3,401	(2,760)	2,320
Interest expense, net	1,779	562	3,681	2,019
Non-core lease costs	1,169	1,323	3,476	4,209
Impairment loss	0	0	31,287	0
Loss on extinguishment of debt	0	0	6,565	0
Other	1,975	1,219	3,316	(5,059)
Adjusted net income	$ 8,611	$ 16,058	$ 792	$ 41,618